Biocept (BIOC) Reports Q4 Loss of $0.87/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Biocept (BIOC) Reports Q4 Loss of $0.87/Share
March 9, 2015 4:05 PM EDT
SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter and Recent Highlights
Strengthened the Company's product line of non-small cell lung cancer (NSCLC) diagnostics through multiple product launches, including:
The launch of...
More
March 9, 2015 4:05 PM EDT
SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter and Recent Highlights
Strengthened the Company's product line of non-small cell lung cancer (NSCLC) diagnostics through multiple product launches, including:
The launch of...
More
March 5, 2015 8:30 AM EST
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq: BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Jason Poole, Ph.D. has joined the Company as Senior Director, Molecular Assay Development.
Dr. Poole brings extensive molecular diagnostic development experience to Biocept. Previously, Dr. Poole was Director, R&D at Trovagene. He has also worked with EMD Millipore as well as... More
